Menu visibility control

Video

Events

Startup Surgery

Most Recent

News

Iris Capital launches €250m European tech investment fund

News

Startup Weekly: Welsh tech accelerator calls for applications, Virgin StartUp partners with WeWork and more

Tech City Voices

Culture. There’s no app for that, Kalanick

Press Releases

‘Connected finance’ app Curve hits £50m spend ahead of UK launch
“Coffee, networking and productivity”: Workspace disruptor ‘Lounge’ launches in London
Kompli-Global’s Technology Will Make Life Harder for Money Launderers

Oxford startup SpyBiotech raises £4m Seed

BioTech
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

SpyBiotech, a startup spun out of Oxford University, has raised £4m in Seed funding from GV (formerly Google Ventures), and Oxford Sciences Innovation (OSI).

The biotech firm has developed a molecular “superglue” designed to tackle diseases and pandemics. The team believes this could be used to create vaccines more quickly than is currently possible.

SpyBiotech will use its new funding to prepare for phase one trials and is initially focusing on virus-like particles (VLPs), which use vaccination to induce immune responses.

Oxford Genetics gets £500,000 from Mercia Technologies

Lachlan MacKinnon, principal at OSI, said: “We see the Spy technology as the missing link in rapid and robust VLP vaccine design and see GV as a natural co-investment partner to take this forward.

“We are privileged to be working with four founders who bring such an impressive combination of academic prowess and clinical-stage experience to the company.”

Gregg Bayes-Brown, marketing and communications manager at Oxford University Innovation, suggested he hopes this ends up being the first in a series of investments made by GV into Oxford University companies.

“We rarely ever see a corporate like GV come in at the seed into university companies. If this is the start of a new trend, it could be massive,” he told The Telegraph.

Earlier this month, London-based biotech firm Pulmocide closed a $30.4m Series B round.

The company, which is run by former GlaxoSmithKline scientists, received investment from SV Life Sciences, Johnson & Johnson’s venture capital arm.

Enter your email address to receive updates straight to your inbox

* indicates required
Send me news on...
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Editor's picks

Paris

Iris Capital launches €250m European tech investment fund
posted 10 hours ago

Startup Weekly: Welsh tech accelerator calls for applications, Virgin StartUp partners with WeWork and more
posted 13 hours ago

Culture. There’s no app for that, Kalanick
posted 15 hours ago

startup life

Uber’s CEO resigns, over £368m in UK tech funding, a new $3.3bn fund and more in The Week in Tech
posted 18 hours ago

inploi-co-founders

EXCLUSIVE: London-based Inploi raises £500,000, brings total to £1m
posted on June 22, 2017

Peter-Smith-Nic-Cary-Feb-2016

UK-founded tech startup Blockchain secures $40m Series B
posted on June 22, 2017